Hepatitis Monthly

Published by: Kowsar

Impact of Pegylated Interferon-alfa-2a on Perforin Level in Patients With Chronic Hepatitis B; Preliminary Study

Meisam Mahdavi 1 , Houshang Amirrasouli 1 , * , Seyed Moayed Alavian 2 , 3 , Bita Behnava 3 , Faranak Kazerouni 1 , Maryam Keshvari 4 , Saeed Namaki 1 , Mohammad Gholami Fesharaki 5 , Hooman Rahimipour 6 , Jahangir Mohammadzade 1 , Farahnaz Zohrehbandian 7 and Fazel Mahdavipour 8
Authors Information
1 Department of Laboratory Sciences, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2 2Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
3 Middle East Liver Diseases Center (MELD Center), Tehran, IR Iran
4 Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, IR Iran
5 Biostatistic Department, Faculty of Medicine, Tarbiat Modares University, Tehran, IR Iran
6 Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
7 Department of Microbiology, Faculty of Basic Sciences, Islamic Azad University, North Tehran Branch, Tehran, IR Iran
8 Faculty of Medicine, Ilam University of Medical Sciences, Ilam, IR Iran
Article information
  • Hepatitis Monthly: November 01, 2013, 13 (11); e11903
  • Published Online: November 23, 2013
  • Article Type: Research Article
  • Received: May 1, 2013
  • Revised: July 21, 2013
  • Accepted: September 28, 2013
  • DOI: 10.5812/hepatmon.11903

To Cite: Mahdavi M, Amirrasouli H, Alavian S M, Behnava B, Kazerouni F, et al. Impact of Pegylated Interferon-alfa-2a on Perforin Level in Patients With Chronic Hepatitis B; Preliminary Study, Hepat Mon. 2013 ; 13(11):e11903. doi: 10.5812/hepatmon.11903.

Copyright © 2013, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Sirianni MC, Campagna M, Scaramuzzi D. Control of human herpes virus type 8-associated diseases by NK cells. Ann N Y Acad Sci. 2007; 1096: 37-43
  • 2. Trambas CM, Griffiths GM. Delivering the kiss of death. Nat Immunol. 2003; 4: 399-403
  • 3. Shen DT, Ma JS, Mather J, Vukmanovic S, Radoja S. Activation of primary T lymphocytes results in lysosome development and polarized granule exocytosis in CD4 + and CD8 + subsets, whereas expression of lytic molecules confers cytotoxicity to CD8 + T cells. J Leukoc Biol. 2006; 80: 827-837
  • 4. Ménager MM, Ménasché G, Romao M, Knapnougel P, Ho CH, Garfa M, et al. Secretory cytotoxic granule maturation and exocytosis require the effector protein hMunc13-4. Nat Immunol. 2007; 8: 257-267
  • 5. Fan Z, Zhang Q. Molecular mechanisms of lymphocyte-mediated cytotoxicity. Cell Mol Immunol. 2005; 2(4): 259-64[PubMed]
  • 6. Catalfamo M, Henkart PA. Perforin and the granule exocytosis cytotoxicity pathway. Curr Opin Immunol. 2003; 15: 522-527
  • 7. Cooksley G, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T, et al. Peginterferon alfa 2a (40KDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat. 2003; 10: 298-305
  • 8. Lau GK, Piratvisuth T, Xian Luo K, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005; 352(26): 2682-2695
  • 9. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology. 2001; 34: 1225-1241
  • 10. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 – summary of a workshop. Gastroenterology. 2001; 120: 1828-1853
  • 11. Hoofnagle JH. Serologic markers of hepatitis B virus infection. Annu Rev Med. 1981; 32: 1-11[DOI]
  • 12. Marcellin P, Bonino F, Lau OK, Farci P, Yurdaydin C, Piratvisuth T, et al. Virological and biochemical response in patients with HBeAg-negative CHB treated with peginterferon alfa 2a lamivudine: 3 years follow-up results [abstract 53]. J Hepatol. 2007; 46(Suppl 1)
  • 13. Bonino F, Chiaberge E, Maran E, Piantino P. Serological markers of HBV infectivity. Ann. Ist. Super. Sanita. 1987; 14(217-230)
  • 14. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B:summary of a clinical research workshop. Hepatology. 2007; 45: 1056–1075
  • 15. Alavian SM. Hepatitis B virus infection in Iran; Changing the epidemiology. Iran J Clin Infect Dis. 2010; 5(1): 51-61
  • 16. Heibein JA, Goping IS, Barry M, Pinkoski MJ, Shore GC, Green DR, et al. Granzyme B-mediated cytochrome C release is regulated by the Bcl-2 family members bid and Bax. J Exp Med. 2000; 192: 1391-1402
  • 17. Bots M, Medema JP. Granzymes at a glance. J Cell Sci. 2006; 119: 5011-5014[DOI]
  • 18. Uellner R, Zvelebil MJ, Hopkins J, Jones J, MacDougall LK, Morgan BP, et al. Perforin is activated by a proteolytic cleavage during biosynthesis which reveals a phospholipid-binding C2 domain. EMBO J. 1997; 16: 7287-7296
  • 19. Kaser A, Enrich B, Ludwiczek O, Vogel W, Tilg H. Interferon-alpha (IFN-alpha) enhances cytotoxicity in healthy volunteers and chronic hepatitis C infection mainly by the perforin pathway. Clin Exp Immunol. 1999; 118(1): 71-7[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments